Sanofi Builds OTC Business Through Organic Growth And Bolt-Ons

Sanofi-Aventis in its latest quarter made headway toward doubling its OTC business by 2014, reporting 7.4 percent organic growth and 26.3 percent growth including acquisitions in the segment

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet